US5545636A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Protein kinase C inhibitors
Assignee: Eli Lilly and Co
•
Filing: 1994-10-18
•
Granted: 1996-08-13
•
Expires: 2014-10-18
Abstract
Abstract The present invention discloses compounds of the general formula: ##STR1## The compounds are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
Inventors
- 👤 William F. Heath, Jr.
- 👤 John H. McDonald, III
- 👤 Michael Paal
- 👤 Gerd R uhter
- 👤 Theo Schotten
- 👤 Wolfgang Stenzel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 08:03
CPC Classifications
C; C07; C07D; C07D401/00; C07D401/14; A; A61; A61P; A61P3/00; A61P3/08; A61P3/10; A61P35/00; C07D403/00; C07D403/14; C07D405/00; C07D405/14; C07D471/00; C07D471/02; C07D471/04; C07H; C07H15/00; C07H15/26
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
167 words
A compound of the formula: ##STR70## wherein: R 1' is hydrogen, C 1 -C 4 alkyl, aminoalkyl, monoalkylaminoalkyl, or dialkylaminoalkyl; R 2' is hydrogen, alkyl, alkoxyalkyl, hydroxyalkyl, C 1 -C 3 alkylthio, S(O)C 1 -C 3 alkyl, or --CF 3 ; R 3 is hydrogen or CH 3 CO--; R 4 , R 4' , R 5 , R 5' , R 6 , R 6' , R 7 and R 7' are independently hydrogen, halogen, alkyl, hydroxy, alkoxy, --COO(C 1 -C 3 alkyl), CF 3 , nitro, amino, acetylamino, monoalkylamino, dialkylamino, alkylthio, C 1 -C 3 alkylthio, or S(O)C 1 -C 3 alkyl; R 8 is (CH 2 ) s R 10 ; R 9 is (CH 2 ) s R 11 ; R 10 and R 11 are independently hydroxy, alkoxy, carboxy, acyloxy, amino, monoalkylamino, dialkylamino, trialkylamino, azido, acylamino, alkoxycarbonyl, cyano, amidino, or aminocarbonyl; r is 1, 2, or 3; s is 0, 1, 2 or 3; or a pharmaceutically acceptable salt or solvate thereof.
Claim 2
Dependent Claim
167 words
A compound of the formula: ##STR70## wherein: R 1' is hydrogen, C 1 -C 4 alkyl, aminoalkyl, monoalkylaminoalkyl, or dialkylaminoalkyl; R 2' is hydrogen, alkyl, alkoxyalkyl, hydroxyalkyl, C 1 -C 3 alkylthio, S(O)C 1 -C 3 alkyl, or --CF 3 ; R 3 is hydrogen or CH 3 CO--; R 4 , R 4' , R 5 , R 5' , R 6 , R 6' , R 7 and R 7' are independently hydrogen, halogen, alkyl, hydroxy, alkoxy, --COO(C 1 -C 3 alkyl), CF 3 , nitro, amino, acetylamino, monoalkylamino, dialkylamino, alkylthio, C 1 -C 3 alkylthio, or S(O)C 1 -C 3 alkyl; R 8 is (CH 2 ) s R 10 ; R 9 is (CH 2 ) s R 11 ; R 10 and R 11 are independently hydroxy, alkoxy, carboxy, acyloxy, amino, monoalkylamino, dialkylamino, trialkylamino, azido, acylamino, alkoxycarbonyl, cyano, amidino, or aminocarbonyl; r is 1, 2, or 3; s is 0, 1, 2 or 3; or a pharmaceutically acceptable salt or solvate thereof.
Claim 3
Dependent Claim
79 words
A compound of claim 1, wherein: R1' is hydrogen, C 1 -C 4 alkyl, aminoalkyl, monoalkylaminoalkyl, or dialkylaminoalkyl; R 3 , R 4 , R 4' , R 5 , R 5' , R 6 , R 6' , R 7 and R 7' are hydrogen; R 8 is (CH 2 ) s R 10 ; R 9 is (CH 2 ) s R 11 ; and R 10 and R 11 are independently hydroxy, amino, monoalkylamino, or dialkylamino.
Claim 4
Dependent Claim
27 words
A method for treating diabetes mellitus, which comprises administering to a mammal in need of such treatment a pharmaceutically effective amount of a compound of claim 1.
Claim 5
Dependent Claim
27 words
A method for treating diabetes mellitus, which comprises administering to a mammal in need of such treatment a pharmaceutically effective amount of a compound of claim 2.
Claim 6
Dependent Claim
20 words
A pharmaceutical formulation comprising a compound of claim 1 and one or more pharmaceutically acceptable carriers, diluents or excipients therefor.
Claim 7
Dependent Claim
20 words
A pharmaceutical formulation comprising a compound of claim 2 and one or more pharmaceutically acceptable carriers, diluents or excipients therefor.
References Cited (Backward Citations)
US4785085A
Cited
US4808613A
Cited
US4923986A
Cited
US5057614A
Cited
US5380746A
Cited
US5292747A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-08-13 | 2000-02-12 | 2000-08-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-08-13 | 2004-02-12 | 2004-08-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-08-13 | 2008-02-12 | 2008-08-13 | $7700.00 | Window Closed / Lapsed |